Analyst Daniel Brennan of TD Cowen maintained a Hold rating on Myriad Genetics, retaining the price target of $7.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Daniel Brennan has given his Hold rating due to a combination of factors tied to both improving trends and remaining uncertainties. He acknowledges that fourth-quarter revenue slightly exceeded prior indications and consensus, and that the 2026 outlook implies faster growth than 2025, supported by rising volumes in key franchises such as hereditary cancer testing, GeneSight, and Prolaris.
At the same time, he notes that projected 2026 growth still falls short of management’s longer-term aspirations and that certain areas, particularly Prenatal, continue to face challenges even if conditions are expected to gradually get better. Brennan therefore keeps a neutral stance while he evaluates how sustainable the momentum in the main growth drivers will be, though he also recognizes that the stock’s sub‑1x EV/Sales valuation could attract greater investor interest if confidence in the acceleration builds.
Brennan covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Natera, and 10x Genomics. According to TipRanks, Brennan has an average return of 19.2% and a 53.59% success rate on recommended stocks.